The Cannabinoid 1 Receptor (CNR1) 1359 G/A Polymorphism Modulates Susceptibility to Ulcerative Colitis and the Phenotype in Crohn's Disease (full – 2010) http://www.ncbi.nlm.nih.gov/pmc/arti...tool=pmcentrez
Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis. (full – 2010) http://www.jpp.krakow.pl/journal/arc...10_article.pdf
The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. (full – 2010) http://www.ncbi.nlm.nih.gov/pmc/arti...0/?tool=pubmed
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. (full – 2010) http://jpet.aspetjournals.org/content/334/3/973.long
The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. (full – 2011)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116968/
Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis (full – 2011)http://www.ncbi.nlm.nih.gov/pmc/arti...0/?tool=pubmed
Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. (full – 2011)http://www.fasebj.org/content/25/8/2711.long
β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. (full – 2011)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070571/
Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. (full – 2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117838/
Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. (abst – 2011)http://www.ncbi.nlm.nih.gov/pubmed/21876860
The JNK inhibitor XG-102 protects against TNBS-induced colitis. (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302790/
Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice. (full – 2012)http://content.karger.com/produktedb...336871&typ=pdf
The atypical cannabinoid O-1602 shows antitumorigenic effects in colon cancer cells and reduces tumor growth in a colitis-associated colon cancer model (full – 2012) http://www.biomedcentral.com/content...-13-S1-A23.pdf
Gut microbiota and the development of obesity. (full – 2012) http://scielo.isciii.es/scielo.php?s...rm=iso&tlng=en
The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. (abst – 2012)http://www.ncbi.nlm.nih.gov/pubmed/22917662
4-Oxo-1,4-dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective Effect Against Experimental Colitis. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/23017078
Role of endogenous cannabinoid system in the gut. (full – 2013) http://www.actaps.com.cn/qikan/manag.../2013-4-12.pdf
O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms (full – 2013)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529923/
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. (full – 2013)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632250/
Pro-resolution, protective and anti-nociceptive effects of a cannabis extract in the rat gastrointestinal tract. (full – 2013)http://www.jpp.krakow.pl/journal/arc...13_article.pdf
Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis. (full – 2013)http://www.nature.com/labinvest/jour...t2012177a.html
Prostaglandin ethanolamides attenuate damage in a human explant colitis model (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23380599
Preventive and therapeutic oral administration of the pentacyclic triterpene α,β-amyrin ameliorates dextran sulfate sodium-induced colitis in mice: The relevance of cannabinoid system. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23454360
Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23706402
3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis. (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23849204
Cannabidiol in inflammatory bowel diseases: a brief overview. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/22815234
Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/24238999
Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24275607
Marijuana use patterns among patients with inflammatory bowel disease. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24185313
Switching cannabinoid response from CB2 agonists to FAAH inhibitors. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24508127
Study uncovers marijuana's potential to treat autoimmune diseases (news – 2014) http://www.news-medical.net/news/201...ediseases.aspx
Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent (full – 2015)http://onlinelibrary.wiley.com/doi/1...bph.12907/full
Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis. (full – 2010) http://www.jpp.krakow.pl/journal/arc...10_article.pdf
The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. (full – 2010) http://www.ncbi.nlm.nih.gov/pmc/arti...0/?tool=pubmed
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. (full – 2010) http://jpet.aspetjournals.org/content/334/3/973.long
The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. (full – 2011)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116968/
Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis (full – 2011)http://www.ncbi.nlm.nih.gov/pmc/arti...0/?tool=pubmed
Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. (full – 2011)http://www.fasebj.org/content/25/8/2711.long
β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. (full – 2011)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070571/
Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. (full – 2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117838/
Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. (abst – 2011)http://www.ncbi.nlm.nih.gov/pubmed/21876860
The JNK inhibitor XG-102 protects against TNBS-induced colitis. (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302790/
Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice. (full – 2012)http://content.karger.com/produktedb...336871&typ=pdf
The atypical cannabinoid O-1602 shows antitumorigenic effects in colon cancer cells and reduces tumor growth in a colitis-associated colon cancer model (full – 2012) http://www.biomedcentral.com/content...-13-S1-A23.pdf
Gut microbiota and the development of obesity. (full – 2012) http://scielo.isciii.es/scielo.php?s...rm=iso&tlng=en
The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. (abst – 2012)http://www.ncbi.nlm.nih.gov/pubmed/22917662
4-Oxo-1,4-dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective Effect Against Experimental Colitis. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/23017078
Role of endogenous cannabinoid system in the gut. (full – 2013) http://www.actaps.com.cn/qikan/manag.../2013-4-12.pdf
O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms (full – 2013)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529923/
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. (full – 2013)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632250/
Pro-resolution, protective and anti-nociceptive effects of a cannabis extract in the rat gastrointestinal tract. (full – 2013)http://www.jpp.krakow.pl/journal/arc...13_article.pdf
Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis. (full – 2013)http://www.nature.com/labinvest/jour...t2012177a.html
Prostaglandin ethanolamides attenuate damage in a human explant colitis model (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23380599
Preventive and therapeutic oral administration of the pentacyclic triterpene α,β-amyrin ameliorates dextran sulfate sodium-induced colitis in mice: The relevance of cannabinoid system. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23454360
Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23706402
3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis. (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23849204
Cannabidiol in inflammatory bowel diseases: a brief overview. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/22815234
Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/24238999
Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24275607
Marijuana use patterns among patients with inflammatory bowel disease. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24185313
Switching cannabinoid response from CB2 agonists to FAAH inhibitors. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24508127
Study uncovers marijuana's potential to treat autoimmune diseases (news – 2014) http://www.news-medical.net/news/201...ediseases.aspx
Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent (full – 2015)http://onlinelibrary.wiley.com/doi/1...bph.12907/full